JPMorgan Chase & Co. Buys 64,010 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX)

JPMorgan Chase & Co. lifted its position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 8,768.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,740 shares of the company's stock after buying an additional 64,010 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.12% of Bicara Therapeutics worth $1,128,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Geode Capital Management LLC purchased a new stake in Bicara Therapeutics in the 3rd quarter worth approximately $1,239,000. Barclays PLC bought a new position in shares of Bicara Therapeutics in the third quarter worth $255,000. Bank of New York Mellon Corp purchased a new stake in shares of Bicara Therapeutics in the fourth quarter worth $701,000. Rhumbline Advisers bought a new stake in Bicara Therapeutics during the fourth quarter valued at $331,000. Finally, Jane Street Group LLC purchased a new position in Bicara Therapeutics during the third quarter worth about $309,000.

Bicara Therapeutics Stock Down 7.0 %

Shares of Bicara Therapeutics stock opened at $14.54 on Monday. Bicara Therapeutics Inc. has a 52-week low of $8.91 and a 52-week high of $28.09. The company has a fifty day moving average of $12.79 and a 200-day moving average of $16.04.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.08). Analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on BCAX shares. Wells Fargo & Company began coverage on Bicara Therapeutics in a research report on Thursday, April 17th. They set an "underweight" rating and a $8.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $13.01 target price on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Wedbush reissued an "outperform" rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research note on Thursday, March 27th. HC Wainwright lowered their price objective on shares of Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating on the stock in a research report on Monday, April 7th. Finally, Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a research report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Bicara Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $32.43.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

Want to see what other hedge funds are holding BCAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.